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Abstract
Chagas' disease caused by Trypanosoma cruzi is an opportunistic infection in the setting of HIV/
AIDS. Some individuals with HIV and chronic T. cruzi infection may experience a reactivation, which
is most commonly manifested by meningoencephalitis. A reactivation myocarditis is the second
most common manifestation. These presentations may be difficult to distinguish from
toxoplasmosis in individuals with HIV/AIDS. The overlap of HIV and Trypanosoma cruzi infection
occurs not only in endemic areas but also in non-endemic areas of North America and Europe
where the diagnosis may be even more difficult. The pathological features, diagnosis and the role
of cytokines in the pathogenesis of the disease are discussed.
Background
In recent years there has been an increasing appreciation
that Chagas' disease, caused by Trypanosoma cruzi, can be
an opportunistic infection in the setting of HIV/AIDS.
Before co-infection with HIV and T. cruzi was recognized
as a syndrome, it was well known that patients with
chronic Chagas' disease who became immunosuppressed
could have a reactivation of their infection.
In the two decades since human immunodeficiency virus
(HIV) infection was first described in the United States,
diverse viral, bacterial, and fungal pathogens have been
identified as causative agents of opportunistic disease. As
our understanding of the pathogenesis and the natural
history of these agents has grown, it has become clear that
these infections are the inevitable consequence of T-cell
depletion and depressed cell-mediated immunity. While
Pneumocystis pneumonia and Toxoplasma encephalitis are
common in the setting of advanced acquired immunode-
ficiency syndrome (AIDS), Chagas' disease in the setting
of HIV infection is less commonly reported. However the
reports of Chagas' disease in AIDS and after blood trans-
fusions and organ transplants highlight the potential for
the reactivation of parasitic diseases with advanced immu-
nosuppression accompanying HIV infection.
The high prevalence of both HIV infection and parasitic
diseases in the tropical and sub-tropical world has
allowed for frequent overlap. Given the immunologic
impact of HIV infection, it is understandable that concur-
rent infection would adversely affect the progression and
natural history of parasitic infections. Considerable evi-
dence has accumulated demonstrating the bi-directional
interactions between parasitic diseases and HIV/AIDS and
the deleterious influence on the natural histories of both
[1-5].
Parasitic diseases have been shown to cause enhanced and
prolonged immune activation [2,6]. Chronic immune
activation by parasites is associated with several signifi-
cant immunologic features. A decline in CD4+ and CD8+
cells, impaired natural killer activity, increased T-cell
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apoptosis, and cellular anergy have all been demon-
strated. These changes have been linked to the preferential
activation of the Th2 type response, which in turn down-
regulate the Th1 type response, hinder macrophage activ-
ity, and weaken the cytotoxic T-cell response [1,6]. Such
responses may lead to a deleterious interaction with HIV
infection.
Some parasitic infections elicit the early production of IL-
4, which eventually promote a Th2 type response. Given
that Th1 mediated cytokines appear crucial in the contain-
ment of HIV infection, the immunologic changes associ-
ated with a predominantly Th2 type response have been
implicated in the progression of HIV infection in the set-
ting of various parasitic diseases [1,6,7]. Parasitic infec-
tion is linked to immune activation, which appears to play
an important role in the progression of HIV disease. In
turn, the progression of HIV disease may be associated
with the immunosuppression that promotes the reactiva-
tion, parasitemia, and clinical manifestations of parasitic
disease [3,6-8]. For example, recent studies in Uganda
have demonstrated that clinical malaria and parasitemia
are significantly more common in HIV-seropositive per-
sons. Studies of pregnant women in Malawi have shown
an increased incidence of malaria in those infected with
HIV [9]. Moreover, clinical data demonstrate a higher HIV
RNA count in persons infected with malaria and a subse-
quent reduction in the viral load after malaria treatment.
Although this does not necessarily prove a cause and effect
linkage, studies in mice have shown a significant increase
in viral p24 after infection with Plasmodium  [2,10].
Another parasitic infection of the tropics, leishmaniasis is
appreciated as an opportunistic infection in individuals
with HIV infection. In vitro studies have shown increased
intracellular growth of Leishmania in HIV-infected macro-
phages. More than half of co-infected persons have detect-
able parasitemia reflecting uncontrolled multiplication
and dissemination [2]. Although African trypanosomiasis
and HIV infection co-exist in sub-Saharan Africa there are
no solid epidemiologic data suggesting that the clinical
course of one is exacerbated by the other.
Clinical disease and epidemiology of Chagas' 
disease
Chagas' disease or American trypanosomiasis, has a wide-
spread distribution from Mexico to Argentina. Although
autochthonous cases in the United States are extremely
rare, the confluence of factors including immigration and
AIDS have led to its emergence as a potential opportunis-
tic infection in immunocompromised persons in Central
and South America. T. cruzi has a complex life cycle that
occurs in insect vectors and mammalian hosts. The vector,
triatomine insects, become infected when it takes a blood
meal from a mammal with circulating trypomastigotes.
These forms transform into epimastigotes in the insect gut
and multiply extracellularly. The epimastigotes ultimately
migrate to the hindgut where they differentiate into non-
dividing metacyclic trypomastigotes, which are dis-
charged in the feces when the insect takes a subsequent
blood meal. Transmissions to a new mammalian host
occurs when the infective metacyclic trypomastigotes con-
taminate mucous membranes, conjunctivas, or breaks in
the skin and invade a variety of host cell types. Once
inside the cell, they transform into amastigotes and mul-
tiply intracellularly. They eventually cause cell rupture
with release of parasites, invade adjacent cells, spread via
the lymphatics and bloodstream to distant sites, and initi-
ate subsequent multiplicative cycles. Transmission has
also been shown to occur by blood transfusions and organ
transplants, transplacentally, and by accidental inocula-
tion in the laboratory [11].
In the naturally acquired infection, a chagoma may
appear at the site of entry. If the portal of entry is the con-
junctiva, the patient may develop painless unilateral peri-
orbital edema termed the Romaña's sign [11].
Dissemination of the parasite may be accompanied by
fever, malaise, edema of the extremities and face, morbil-
liform rash, generalized lymphadenopathy, and hepat-
osplenomegaly. If heavy tissue parasitism occurs,
clinically significant myocarditis may ensue in a small
proportion of patients occasionally leading to congestive
heart failure and death. Life threatening arrhythmias, typ-
ical of chronic cardiac Chagas' disease, usually do not
occur in acute Chagas' disease. Amastigotes may parasitize
cells of the gray and white matter of the central nervous
system in acute infection and cause meningoencephalitis,
especially in young children. When this occurs, it is usu-
ally in conjunction with acute myocarditis and is associ-
ated with a very poor prognosis. The signs and symptoms
of acute Chagas' disease usually abate within 4–8 weeks.
They then enter the indeterminate phase in which the par-
asite is contained by the host's immune system or is
sequestered in intracellular spaces protected from destruc-
tion. This phase is characterized by the lack of overt symp-
toms, detectable antibodies to T. cruzi, and subclinical
parasitemia [11].
Chronic Chagas' disease may become clinically evident
years or decades after the initial infection. Symptoms
develop in only 10–30% of chronically infected persons,
with cardiac manifestations as the predominant findings
[11]. Congestive heart failure, arrhythmias, thrombosis,
dizziness and syncope are typical findings. However, sei-
zures are rare in chronic Chagas' disease, unless related to
a thrombo-embolic event. Although there have been disa-
greements concerning the pathogenic basis of chronic
chagasic cardiomyopathy; persistence of parasites,
autoimmunity, and microvascular dysfunction have all
been cited as etiologic factors leading to progressive organKinetoplastid Biology and Disease 2004, 3 http://www.kinetoplastids.com/content/3/1/2
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dysfunction. The cardiomyopathy develops insidiously
often affecting the right ventricle preferentially. Once con-
gestive heart failure ensues, life expectancy is limited. The
gastrointestinal tract is also frequently affected in chronic
Chagas' disease. Megaesophagus is the most common
clinical expression with symptoms similar to that of idio-
pathic achalasia such as chest pain, dysphagia,
odynophagia, cough, and regurgitation. Hypersalivation,
parotid enlargement, and repeated aspiration may also
occur. Constipation and abdominal pain are the typical
symptoms of patients with megacolon. In patients with
advanced megacolon, obstruction, perforation, and sepsis
may develop.
Although the incidence of reactivation of Chagas' disease
in the setting of immunosuppression is unknown, it often
follows a more severe clinical course than the Chagas' dis-
ease in an immunocompetent person [7]. Reactivation of
Chagas' disease has been described in patients with leuke-
mia, and with kidney and heart transplantation. While
central nervous system involvement has not been
described in chronic Chagas' disease in immunocompe-
tent patients, it is a common presentation of reactivation
of Chagas' disease acquired years prior to the onset of
immunosuppression [12-16].
Chagas' disease and AIDS
Chagas' disease/HIV co-infection has been well described
in the literature [5] since the initial report by del Castillo
et al [13]. In 1990, Del Castillo and colleagues reported
the first clinical observation of Chagas' disease and AIDS.
They described the case of a 19-year old man with hemo-
philia B who presented with fever, headaches, photopho-
bia, and weight loss. A CT scan of the brain revealed a
large hypodense lesion comprising the right frontal lobe
with mass effect and herniation. Suspecting a glioma, the
patient underwent an emergent neurosurgical resection of
the lesion. Subsequent pathologic examination revealed
inflammatory perivascular infiltrates and clusters of T.
cruzi amastigotes. Chagas' and HIV-1 serology were both
positive and the CD4 cell count was low. He was treated
with nifurtimox for 4 weeks with stabilization of his neu-
rologic symptoms. However the patient's clinical course
was complicated by acute myocarditis and he later died of
respiratory failure [13]. This clinical presentation high-
lights several key aspects concerning the presentation of
Chagas' disease in AIDS. The central nervous system is the
most commonly affected site, occurring in roughly 75% of
cases [13,15,16]. Space occupying lesions are commonly
seen with Chagas' disease in AIDS. The classic manifesta-
tions are that of an acute meningoencephalitis, with fever,
headaches, seizures, vomiting, and focal neurological def-
icits. Examination of the cerebrospinal fluid may show
mild pleocytosis with lymphocyte predominance,
increased protein, and the presence of T. cruzi trypomas-
tigotes [4,13,15,16]. These findings are typical for acute
Chagas' disease in the immunocompetent as well as for
reactivated Chagas' disease in the immunocompromised.
Brain imaging by CT scan often reveals a single or multi-
ple hypodense subcortical lesions with or without
enhancement. The lesions predominantly involve the
white matter of the brain. Histopathologic examination
reveals severe inflammation associated with numerous
amastigotes parasitizing glial cells and occasionally neu-
rons [17]. Although central nervous system Toxoplamsa
gondii infection in AIDS patients involves the basal gan-
glia and thalamus more commonly, the lesions of central
nervous system Chagas' disease are often mistakenly
attributed to this parasite as well as other opportunistic
infections. This lack of specificity of brain imaging and the
broad differential of space occupying lesions in individu-
als with AIDS underscore the usefulness of a brain biopsy
to affect accurate diagnosis and appropriate therapy.
The heart is the next most commonly affected organ rec-
ognized in 25% to 44% of cases [11]. Myocarditis as the
singular manifestation of Chagas' disease in HIV-infected
patients is uncommon. It is usually associated with central
nervous system involvement and is diagnosed clinically or
at autopsy [11,17]. Findings from necropsy studies sug-
gest that a significant proportion of Chagas' disease in
HIV/AIDS have clinically silent cardiac disease despite
brisk inflammation with nests of parasites in the myocar-
dium [17]. Clinical manifestations are those of heart fail-
ure and arrhythmias. Another key aspect found in HIV-
infected patients who present with clinically symptomatic
Chagas' disease is that of significant immunosuppression.
Chagas' disease in HIV infected patients has been predom-
inantly described in those with advanced disease with
CD4 counts below 200 cells/ml [3,4,13,15,16].
The histopathology of the central nervous system and the
heart associated with reactivated Chagas' disease in AIDS
has been well described [3,8,17]. The brain is grossly
enlarged in size and weight with scattered areas of soften-
ing and hemorrhage. The white matter appears to be more
involved than the gray matter. Microscopically, menin-
goencephalitis with necrosis and hemorrhage are found in
the scattered areas of softening. Meningitis is present in
varying degrees of intensity. Macrophages and lym-
phocytes account for the majority of the inflammatory
infiltrate noted in the parenchyma and perivascular
spaces, followed by plasma cells and granulocytes. Micro-
glial nodules and disseminated multifocal astrocytic glio-
sis of the white matter are invariable found in most of the
cases. Heavy parasitism is noted in glial cells and in areas
of necrosis and hemorrhage. Parasites are also found in
macrophages, around blood vessels, free in intercellular
spaces but rarely in neuronal cells [3,17]. The findings in
the myocardium vary with the intensity of the inflamma-Kinetoplastid Biology and Disease 2004, 3 http://www.kinetoplastids.com/content/3/1/2
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tion provoked by T. cruzi parasitism. The myocarditis may
be mild with limited focal, intrafascicular or endomysial
infiltrates with macrophages and lymphocytes or it may
be more severe with extensive and more widespread foci
of inflammatory infiltrates. The inflammatory process has
been observed in every layer, from the endocardium to the
epicardium. Often the inflammatory cells can be seen dis-
secting one myocardial cell from another. Another feature
of cardiac involvement is the proliferation of connective
tissue, which may be diffuse with several areas connected
by bridging fibrous fascicles [11,17,18]. Although the pre-
cise mechanisms that drive the pathogenesis of Chagas'
disease have not been fully defined, clinical studies and
experimental models suggest that the severity of tissue
parasitism during acute disease correlates with the symp-
tomatic and pathologic findings in chronic reactivated
disease.
As more cases have been reported, we have gained a better
understanding of the interaction between T. cruzi and HIV
during coinfection. Upon review of the case reports and
case series of investigators such as Ferreira and Sartori
from Brazil, it appears that the clinical manifestations of
Chagas' disease in the HIV-infected represent reactivation
and not primary infection with T. cruzi [4,7,13,15,19].
This is similar to T. gondii, which is regarded by some as
the prototypical opportunistic infection, which is
acquired years prior to presentation, remains in latency
for an indeterminate time, and only reactivates in the set-
ting of AIDS to cause symptoms and disease. The cases of
Chagas' disease and HIV infection that have been reported
are described in patients presenting to tertiary care hospi-
tals situated in urban centers. Although Chagas' disease
may be endemic in these urban areas, vector-borne trans-
mission usually does not occur there. The typical epidemi-
ologic sequence of events is for patients to acquire T. cruzi
infections while residing in rural areas of endemicity, to
move to urban areas where they acquire HIV infection,
and to present clinically as immunosuppression ensues
and T. cruzi reactivates [3,13,15,16,19].
The level of parasitemia observed in HIV infected individ-
uals with symptoms of Chagas' disease is useful in diagno-
sis [2,20]. Direct microscopic examination of blood and
cerebrospinal fluid may reveal T. cruzi trypomastigotes
[20]. This finding may precede the clinical manifestations
of disease or it may be discovered with the onset of symp-
toms. Studies by Perez Ramirez and Sartori demonstrate
that HIV-infection lead to a substantial increase of T. cruzi
parasitemia in patients with Chagas' disease [4,7,21].
Moreover, the reactivation of Chagas' disease and its sub-
sequent parasitemia has been shown to be associated with
an increase in plasma HIV-1 viral load [4]. Other studies
have shown an increased frequency of detection of T. cruzi
parasitemia in HIV-seropositive subjects with chronic
Chagas' disease than in HIV-seronegative subjects, a
higher level of parasitemia as established by xenodiagno-
sis, and a higher level of parasitemia in AIDS than in less
advanced HIV infection [19]. Importantly, mice coin-
fected with murine leukemia virus, which causes immun-
odeficiency, and T. cruzi have greater parasitemia, and
myocardial parasitism with inflammation than do mice
infected with T. cruzi alone [22].
HIV-infected individuals have defects in cell-mediated
immunity including decreased lymphocyte proliferation
and decreased production of IL-12 and IFN-γ, which are
often associated with progression of HIV infection. These
deficiencies are among the contributory factors leading to
opportunistic infection and may appear prior to CD4+T-
cell depletion. It has recently been demonstrated that
CD154, a molecule expressed on activated CD4+ T cells is
important in the regulation of both cell mediated and
humoral immunity and critical for the resistance to
opportunistic infections. In CD4+ T cells from HIV
infected patients the expression of CD154 was impaired
in response to a number of pathogens including T. gondii.
There was a correlation with decreased production of IL-
12 and IFN-γ in response to Toxoplasma [23]. These
observations could be applicable to T. cruzi. Various stud-
ies point to the crucial role of cytokines such as interferon
(IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-
12, and nitric oxide in host resistance and susceptibility in
T. cruzi infection [6]. IFN-γ and TNF-α have been impli-
cated in the activation of macrophages during the acute
phase of the infection [4,6]. These two cytokines induce
high levels of nitric oxide, which may contribute to the
control of parasite replication. Mice deficient in IFN-γ
have higher parasitemia and myocardial parasitism but
lower myocardial inflammation and earlier mortality. In
contrast, mice deficient in IL-12 have milder parasitemia
and myocardial parasitism but greater myocardial inflam-
mation and later mortality. Michailowsky and colleagues
have described the role of cytokines in tissue parasitism.
In a series of experiments with mice, expression of IL-12
and IFN-γ has been shown to increase susceptibility to the
Colombian strain of T. cruzi. In contrast, IL-4 expression
has been associated with lower parasitemia and mortality
[6].
Earlier studies have postulated a correlation between
genetic diversity in T. cruzi and variability in clinical dis-
ease [21,24]. Murine models have demonstrated the dif-
ferent tissue tropism of T. cruzi as illustrated by the
Colombian strain's affinity for the heart and brain [6]. In
reactivated Chagas' disease and HIV coinfection, several
strains of T. cruzi may be discovered through genetic and
phylogenetic testing in any given patient. Studies by
Pacheco and Perez-Ramirez have not found a correlation
between a particular genotype and the reactivation ofKinetoplastid Biology and Disease 2004, 3 http://www.kinetoplastids.com/content/3/1/2
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Chagas' disease in HIV-seropositive patients [21,24]. On
the other hand, Marques de Brito has demonstrated that
mice infected with a particular genotypic strain express a
genetically divergent strain after immunosuppression
[25]. However, current evidence does not support a clear
link between genetic variability and clinical disease in
humans.
The treatment of acute T. cruzi infection is with Benznida-
zole or Nifurtimox. The usual dosing regimen for Benzni-
dazole is 5–7 mg/kg per day in 2 divided doses for 30–90
days. The usual dosing regimen for Nifurtimox is 8–10
mg/kg per day in 3–4 divided doses for 90–120 days.
However, the duration of therapy has not been studied in
HIV/AIDS, but in the absence of immune reconstitution
chronic suppressive therapy would likely be required. In a
somewhat analogous situation, many patients with Cha-
gas' disease undergoing organ transplantation have
required therapy during the period of immunosuppres-
sion.
Summary
We have attempted to highlight some of the knowledge
gained in the decade following the first description of
Chagas' disease in the HIV-seropositive population. Now
well recognized as an opportunistic infection in AIDS,
more cases can be expected given the confluence of certain
demographic and epidemiologic trends. Chagas' disease is
widely distributed in Central and South America affecting
18 million people in 21 different countries [2,11]. As this
population overlaps and intersects with the growing HIV-
seropositive population, the incidence of disease is likely
to increase. Moreover as persons continue to migrate from
endemic areas, the potential for new cases in the United
States, Canada and Europe will also increase. Clinicians
and researchers will have to consider the risk of reactiva-
tion of latent T. cruzi infection in their approach toward
immunocompromised patients with relevant exposures.
This is particularly important when one considers that the
efficacy of specific anti-parasitic drug therapy has not been
evaluated in the setting of HIV/AIDS in a systematic man-
ner.
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